Metachronous Second Primary in the Form of Nasopharyngeal Carcinoma Following Treatment of Small Cell Neuroendocrine Carcinoma of the Head and Neck: Dual Tracer PET/CT Findings Highlighting SSTR2 Expression and Its Theranostic Implications

Abstract

Patients of head and neck squamous cell carcinoma (HNSCC) experience increased risk of developing second primary cancer (SPC) necessitating active surveillance during their disease course. SPCs are associated with poor prognosis and are the leading cause of long-term morbidity and mortality impacting survival of patients with HNSCC. Small cell neuroendocrine carcinoma (SmNEC) is a rare but aggressive neoplasm with poor prognosis and high risk of local recurrence and distant metastasis. We report an exceedingly rare case of nasopharyngeal carcinoma (NPC) presenting as a recurrence in the form of metachronous second primary to primary SmNEC 9 years after chemotherapy. The dual tracer positron emission tomography and computed tomography (PET/CT) imaging approach ([⁶⁸Ga]Ga-DOTATATE-PET/CT with ¹⁸F-FDG-PET/CT) was explored in such metachronous NPCs, and the findings are illustrated with its potential for theranostic applications. NPC is a rare malignancy with significant geographical variations in incidence rates. Somatostatin receptor 2 (SSTR2) expression in NPC is well documented and can serve as a potential theragnostic marker in advanced NPC where the successful outcome is minimal with currently available treatment modalities.

Keywords

sinonasal carcinoma - small cell neuroendocrine carcinoma - NEC - ¹⁸F-FDG - [⁶⁸Ga]Ga-DOTATATE - nasopharyngeal carcinoma - metachronous second primary malignancy

Publication History

Article published online:
30 September 2024

• References

• 1 Chuang SC, Scelo G, Tonita JM. et al. Risk of second primary cancer among patients with head and neck cancers: a pooled analysis of 13 cancer registries. Int J Cancer 2008; 123 (10) 2390-2396
• 2 van der Schroeff MP, van de Schans SA, Piccirillo JF, Langeveld TP, Baatenburg de Jong RJ, Janssen-Heijnen ML. Conditional relative survival in head and neck squamous cell carcinoma: permanent excess mortality risk for long-term survivors. Head Neck 2010; 32 (12) 1613-1618
• 3 Adjei Boakye E, Buchanan P, Hinyard L, Osazuwa-Peters N, Schootman M, Piccirillo JF. Incidence and risk of second primary malignant neoplasm after a first head and neck squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 2018; 144 (08) 727-737
• 4 Muir CS, Percy C. Cancer registration: principles and methods. Classification and coding of neoplasms. IARC Sci Publ 1991; 95: 64-81
• 5 Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6 (05) 963-968
• 6 Lubin JH, Purdue M, Kelsey K. et al. Total exposure and exposure rate effects for alcohol and smoking and risk of head and neck cancer: a pooled analysis of case-control studies. Am J Epidemiol 2009; 170 (08) 937-947
• 7 Pointer KB, Ko HC, Brower JV. et al. Small cell carcinoma of the head and neck: an analysis of the National Cancer Database. Oral Oncol 2017; 69: 92-98
• 8 Rivero A, Liang J. Sinonasal small cell neuroendocrine carcinoma: a systematic review of 80 patients. Int Forum Allergy Rhinol 2016; 6 (07) 744-751
• 9 Rosenthal DI, Barker Jr JL, El-Naggar AK. et al. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer 2004; 101 (11) 2567-2573
• 10 Naito Y, Yamada K, Imamura Y. et al. Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer. Med Oncol 2018; 35 (05) 61
• 11 Ozturk K, Gencturk M, Caicedo-Granados E, Li F, Cayci Z. Utility of FDG PET/CT in the characterization of sinonasal neoplasms: analysis of standardized uptake value Parameters. AJR Am J Roentgenol 2018; 211 (06) 1354-1360
• 12 Liu KY, Goldrich DY, Ninan SJ. et al. The value of ⁶⁸Gallium-DOTATATE PET/CT in sinonasal neuroendocrine tumor management: a case series. Head Neck 2021; 43 (06) E30-E40
• 13 Adnan A, Basu S. Combined ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy and platinum-based chemotherapy in recurrent, metastatic sinonasal neuroendocrine carcinoma: a promising therapeutic option. J Nucl Med Technol 2020; 48 (03) 292-294
• 14 Lin CH, Chiang TP, Shum WY. et al. Primary small cell neuroendocrine carcinoma of the nasal cavity after successful curative therapy of nasopharyngeal carcinoma: a case report. Kaohsiung J Med Sci 2009; 25 (03) 145-150
• 15 Madhusudhan K, Hassan N, Shukri N, Hitam S, Bakrin I. Small cell neuroendocrine carcinoma: a rare second primary malignancy after treatment of nasopharyngeal carcinoma. Romanian Journal of Rhinology 2018; 8: 187-192
• 16 Haleshappa RA, Thanky AH, Kuntegowdanahalli L, Kanakasetty GB, Dasappa L, Jacob L. Epidemiology and outcomes of nasopharyngeal carcinoma: experience from a regional cancer center in Southern India. South Asian J Cancer 2017; 6 (03) 122-124
• 17 Yang SS, Wu YS, Chen WC. et al. Benefit of [¹⁸F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging 2022; 49 (03) 980-991
• 18 Mohandas A, Marcus C, Kang H, Truong MT, Subramaniam RM. FDG PET/CT in the management of nasopharyngeal carcinoma. AJR Am J Roentgenol 2014; 203 (02) W146-W157
• 19 Schartinger VH, Dudás J, Url C. et al. (68)Ga-DOTA (0)-Tyr (3)-octreotide positron emission tomography in nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging 2015; 42 (01) 20-24
• 20 Lechner M, Schartinger VH, Steele CD. et al. Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. Nat Commun 2021; 12 (01) 117
• 21 Xu Y, Quan Z, Zhan Y. et al. SSTR2 positively associates with EGFR and predicts poor prognosis in nasopharyngeal carcinoma. J Clin Pathol 2023; jcp-2023-208987
• 22 Zhao L, Pang Y, Wang Y. et al. Somatostatin receptor imaging with [⁶⁸Ga]Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging 2022; 49 (04) 1360-1373
• 23 Zheng J, Wang G, Ru Q. et al. A head-to-head comparison of [⁶⁸Ga]Ga-DOTATATE and [⁶⁸Ga]Ga-FAPI PET/CT in patients with nasopharyngeal carcinoma: a single-center, prospective study. Eur J Nucl Med Mol Imaging 2024; 51 (11) 3386-3399
• 24 Bossi P, Chan AT, Licitra L. et al; ESMO Guidelines Committee. Electronic address: [e-mail], EURACAN. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up^† . Ann Oncol 2021; 32 (04) 452-465
• 25 Basu S, Sirohi B, Shrikhande SV. Dual tracer imaging approach in assessing tumor biology and heterogeneity in neuroendocrine tumors: its correlation with tumor proliferation index and possible multifaceted implications for personalized clinical management decisions, with focus on PRRT. Eur J Nucl Med Mol Imaging 2014; 41 (08) 1492-1496